March 22, 2019

Guselkumab Self-Injector for Plaque Psoriasis Gets FDA Approval

By Jennifer Barrett, Associate Editor
Published Online: Monday, Mar 04, 2019

Guselkumab (Tremfya, Janssen), a single-dose, patient controlled injector for adults with moderate-to-severe plaque psoriasis, has been approved by the FDA and is now available in the United States, according to a press release.

The first FDA-approved medication of its kind to offer the One-Press patient-controlled injector, guselkumab is administered as a 100 mg subcutaneous injection once every 8 weeks, after starter doses at weeks 0 and 4. Designed for self-injection, the One-Press offers a controlled injection and hides the needle throughout the process. 

In the phase 3, multicenter and randomized ORION study, patient experience with One-Press was assessed through a validated Self-Injection Assessment Questionnaire (SIAQ). Through this survey, patients could evaluate their experience at weeks 0, 4, and 12 on a scale of 0 to 10, with 0 being the worst and 10 the best, across 6 domains:
  • Feelings about injections
  • Self-image
  • Self-confidence
  • Pain
  • Skin reactions during or after the injection
  • Ease of use with the self-injection device
  • Satisfaction with self-injection 
The mean score for “Satisfaction with Self-Injection” was 9.18 (with 10 indicating “Very Satisfied”) and the mean score for “Ease of Use” was 9.24 (with 10 indicating “Very Easy”).

The study also evaluated efficacy and safety. A greater proportion of patients in the guselkumab group achieved an IGA score of 0 or 1 or a PASI 90 response at week 16 (81% and 76%, respectively) than in the placebo group (0% for both endpoints). The proportion of patients who achieved an IGA score of 0 at week 16 was higher in the guselkumab group compared to the placebo group (56% vs. 0%). The proportion of patients who achieved a PASI 100 response at week 16 was higher in the guselkumab group compared to the placebo group (50% vs. 0%).

Nearly 99% of patients reported a successful first injection. After 3 injections, patients still reported favorable outcomes with the device’s usability.

Guselkumab is intended for use under the guidance and supervision of a physician, and patients may self-inject with guselkumab One-Press after physician approval and proper training, according to Janssen.

References

Janssen Announces U.S. FDA Approval of Novel TREMFYA® (guselkumab) One-Press Patient-controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis. Janssen website. https://www.janssen.com/janssen-announces-us-fda-approval-novel-tremfyar-guselkumab-one-press-patient-controlled-injector. Published Feb. 27, 2019. Accessed 27, 2019.

About the Specialty Pharmacy Times Industry Guide

The Specialty Pharmacy Times Industry Guide includes comprehensive editorial content relative to all specialty pharmacy stakeholders. Content includes information relative to market trends, commercialization, distribution, order to cash, HUB Services, managed care strategies and DIR fees. The guide also includes profiles, and a complete list of stakeholders along the patient journey: specialty pharmacies, wholesaler distributors, manufacturers, support services, group purchasing, and trade associations.

Sign Up for the Industry Guide Newsletter

Copyright © 2006-2018 Pharmacy & Healthcare Communications, LLC
All Rights Reserved

About Us